Loading. Until this page reports where its figures came from, treat them as placeholders and do not quote them.

Health, Disability and Ageing

National Blood Authority

A. Non-corporate Commonwealth Entity · Material materiality · Who this agency buys from, and what expires when. The expiry pipeline is where the next tender comes from.

Contract spend

783.5$m

FY2025-26, apportioned

Contracts

active in FY2025-26

Supplier groups

resolved to parent

Apportioned contract spend, FY2025-26, amendment-adjusted, cancelled contracts excluded, straight-line by calendar day.

Contract spend over time

National Blood Authority's apportioned contract spend, FY2021-22 to FY2025-26, in $m. Contracts are spread across financial years by calendar day; AusTender holds nothing signed before 1 July 2018, so earlier years are understated and are not shown.

Largest suppliers

The 5 largest supplier groups by apportioned FY2025-26 value, after entity resolution, so a prime does not fragment across spellings of its own name. Values are $m of contract value apportioned to this financial year, not cash paid.
Supplier group	FY2025-26 $m
CSL BEHRING (AUSTRALIA) PTY LTD	351.1
Grifols Australia Pty Ltd	127.8
Roche Products Pty Ltd	105.8
TAKEDA PHARMACEUTICALS AUSTRALIA PTY LTD	75.5
Octapharma Australia Pty Ltd	47.1

Behind this point

Full agency detail

65 more suppliers; 37 contracts worth $441.4m expiring in the 12 months to 2 October 2027; 0 buying divisions and 12 categories.

Included: every supplier group with its parent and how it was resolved; the expiry pipeline month by month with values; the buying-division breakdown; the UNSPSC category mix; open versus limited tender share; and supplier concentration. Portfolio and national views, this agency's top line and its trend stay free for everyone.